Medtronic, Alnylam and CHDI will develop a drug-device combo

11/3/2010 | Mass High Tech (Boston)

Alnylam Pharmaceuticals will work with Medtronic and CHDI Foundation to develop ALN-HTT, an RNAi-based drug for Huntington's disease that can be delivered by Medtronic's implantable infusion device. CHDI will fund as much as 50% of requirements necessary for seeking regulatory approval of the drug-device combination. Medtronic and Alnylam will have an equal share in the partnership in the U.S.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN